Alcon to Acquire Aerie Pharmaceuticals for US$770 M.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      In order to expand its presence in the ophthalmic pharmaceutical eye drop space, Alcon has entered into a definitive merger agreement with Aerie Pharmaceuticals through which Alcon will acquire Aerie for US$15.25 per share. The transaction, worth approximately US$770 M, will provide Alcon with access to two marketed glaucoma medicines, Rhopressa® and Rocklatan®, as well as a pipeline of experimental therapies. Since early 2021, Alcon has also acquired the US rights to Novartis' glaucoma eye drop, Simbrinza®, as well as two products from Kala Pharmaceuticals that treat dry eye disease and post-surgical inflammation. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of PharmaDeals Review is the property of IMS Health and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)